证券代码：300723 证券简称：一品红 公告编号：2025-043 一品红药业集团股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十次会议审议通 过，决定于 2025 年 7 月 1 日召开 2025 年第二次临时股东大会。现将本次会议的相关事 项通知如下： 一、召开会议的基本情况 （一）股东大会届次：本次股东大会为 2025 年第二次临时股东大会。 （二）股东大会的召集人：公司董事会 （三）会议召开的合法合规性：经公司第四届董事会第十次会议审议通过决定召开 本次会议，本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 （四）会议召开的日期、时间： 1、现场会议召开日期、时间：2025 年 7 月 1 日（星期二）下午 14：30 2、网络投票时间：2025 年 7 月 1 日。 ①通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 1 日上午 9:15-9:25，9:30-11:30， ...

证券代码：300723 证券简称：一品红 公告编号：2025-042 一品红药业集团股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十次会 议于 2025 年 6 月 14 日下午 14:30 以现场结合通讯表决方式召开。本次会议通知 于 6 月 13 日以电话或电子邮件等方式向全体董事发出，经全体董事同意豁免会 议通知时间要求。会议由董事长李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。本次会议的召集、召开和表决程序符合《中华 人民共和国公司法》等法律法规以及《一品红药业集团股份有限公司章程》的有 关规定。 二、董事会会议审议情况 一品红药业集团股份有限公司董事会 2025 年 6 月 15 日 1、审议通过《关于提请召开 2025 年第二次临时股东大会的议案》 公司拟定于 2025 年 7 月 1 日 14：30 召开公司 2025 年第二次临时股东大会 现场会议，会议采取现场投票表决与网络投票相 ...

Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]

Core Insights - The recombinant protein sector saw a rise of 1.42%, ranking 8th among concept sectors, with 26 stocks increasing in value, including Sai Sheng Pharmaceutical which hit a 20% limit up [1] - Major gainers in the sector included Jie Ya Co., Yi Pin Hong, and Zhong Yuan He He, with increases of 14.83%, 9.40%, and 6.85% respectively [1] - The sector experienced a net outflow of 223 million yuan in capital, with 13 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflows [2] Stock Performance - Sai Sheng Pharmaceutical led the net inflow with 165 million yuan, followed by Zhong Yuan He He, Ke Xing Pharmaceutical, and Yi Pin Hong with net inflows of 62.43 million yuan, 36.45 million yuan, and 28.04 million yuan respectively [2][3] - The top stocks by net inflow ratio included Sai Sheng Pharmaceutical at 23.69%, *ST Su Wu at 11.75%, and Ke Xing Pharmaceutical at 9.86% [3] Market Trends - The recombinant protein sector's performance was contrasted by other sectors, with the transgenic sector leading with a 3.15% increase, while EDR concept saw a decline of 2.63% [2] - The overall market sentiment reflected a mixed performance across various sectors, indicating selective investor interest [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

10日，A股、港股午后全线回落，创业板指、科创50指数等跌超1%，恒生科技指数跌近1%。 具体来看，两市股指早盘窄幅震荡，午后加速下探。截至收盘，沪指跌0.44%报3384.82点，深证成指跌0.86% 报10162.18点，创业板指跌1.17%报2037.27点，科创50指数跌1.47%，北证50指数跌约1%，沪深北三市合计成 交14516亿元，较此前一日增加近1400亿元。 场内超4000股飘绿，半导体、军工、石油、券商、酿酒等板块走低；银行板块走强，民生银行一度涨约4%， 兴业银行、南京银行盘中创出新高；农业板块拉升，种业股表现亮眼，秋乐种业、康农种业涨超10%；离境退 税概念崛起，国航远洋30%涨停，宁波海运、南京港、连云港等涨停；创新药概念再度活跃，昂利康连续3日 涨停，一品红、泰恩康涨超9%均创出新高；稀土概念持续强势，中科磁业、科恒股份等涨停；短剧概念尾盘 异动，中文在线涨超13%，慈文传媒涨停；体育概念热度不减，共创草坪斩获7连板。 离境退税概念盘中大幅走高，截至收盘，国航远洋30%涨停，华光源海涨近27%，宁波远洋、南京港、连云港 等均涨停。 | 代码 | 名称 | 4 | 涨幅% | 现价 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：300723 证券简称：一品红 公告编号：2025-041 一品红药业集团股份有限公司 关于全资子公司获得盐酸右美托咪定注射液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸右美托咪定 注射液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：盐酸右美托咪定注射液 英文名/拉丁名：Dexmedetomidine Hydrochloride Injection 主要成份：盐酸右美托咪定 剂 型：注射剂 注册分类：化学药品 3 类 规 格：2ml:0.2mg（按 C13H16N2计） 药品注册标准编号：YBH12292025 药品有效期：24 个月 上市许可持有人：广州一品红制药有限公司 上市许可持有人地址：广州市经济技术开发区东区东博路 6 号 生产企业：河北凯威制药有限责任公司 生产企业地址：河北省张家口市宣化县沙岭子镇（东山产业集聚区） 药品批准文号：国药准字 H2025441 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration of Dexmedetomidine Hydrochloride Injection, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Dexmedetomidine Hydrochloride Injection [1] - The main ingredient of the drug is Dexmedetomidine Hydrochloride, and it is formulated as an injection with a specification of 2ml:0.2mg (calculated as C13H16N2) [1] - The registration classification for this drug is categorized as Class 3 chemical drugs [1]

证券代码：300723 证券简称：一品红 公告编号：2025-039 一品红药业集团股份有限公司 关于全资子公司获得间苯三酚注射液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州市联瑞 制药有限公司于近日收到国家药品监督管理局核准签发的关于间苯三酚注射液 的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：间苯三酚注射液 英文名/拉丁名：Phloroglucinol Injection 主要成份：间苯三酚 剂 型：注射剂 注册分类：化学药品 4 类 规 格：4ml:40mg（按 C6H6O3•2H2O 计） 药品注册标准编号：YBH10562025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格：10 支/盒 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上 ...